NCT07404254

Brief Summary

This study will evaluate post-beverage subjective caffeine responses and physiological responses to caffeinated beverage variations in generally healthy adults.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
75

participants targeted

Target at P75+ for not_applicable healthy

Timeline
Completed

Started Jan 2026

Shorter than P25 for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 5, 2026

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

January 12, 2026

Completed
1 month until next milestone

First Posted

Study publicly available on registry

February 11, 2026

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2026

Completed
Last Updated

February 11, 2026

Status Verified

February 1, 2025

Enrollment Period

3 months

First QC Date

January 12, 2026

Last Update Submit

February 9, 2026

Conditions

Keywords

caffeine beverages in health and well-being

Outcome Measures

Primary Outcomes (1)

  • Subjective caffeine visual analog scales

    Participants will rate how they feel on a horizontal line. Lines will be flanked with perceived feelings. Scores range from 0-100, where a higher score indicates increase in that feeling.

    Day 5

Secondary Outcomes (4)

  • Subjective caffeine visual analog scales

    Up to 5 hours after beverage consumption

  • Subjective quality of life ratings

    Day 5

  • Physiological response - Sleep

    Up to 5 hours post-beverage consumption and after 5 days of daily beverage consumption

  • Physiological responses - Activity

    Up to 5 hours post-beverage consumption and after 5 days of daily beverage consumption

Other Outcomes (2)

  • Physiological responses - Heart rate

    Up to 5 hours post-beverage consumption and after 5 days of daily beverage consumption

  • Subjective beverage experience ratings

    Day 5

Study Arms (3)

Caffeinated, low sugar beverage

ACTIVE COMPARATOR
Other: Caffeinated, low sugar beverage

Caffeinated beverage

ACTIVE COMPARATOR
Other: Caffeinated beverage

Control beverage

PLACEBO COMPARATOR
Other: Control beverage

Interventions

Participants will consume a caffeinated beverage with variations in sweetener and caffeine content.

Caffeinated, low sugar beverage

Participants will consume a caffeinated beverage with variations in sweetener and caffeine content.

Caffeinated beverage

Participants will consume a caffeinated beverage with the control level of sweetener and caffeine content.

Control beverage

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Males or females, ≥18 to ≤55 years of age
  • BMI ≥18.5 and \<35.0 kg/m2
  • Generally good health
  • Participant currently and consistently has a sweetened caffeine routine
  • Participant is willing to substitute their current caffeine routine for the test beverage daily
  • Participant has never consumed the test beverage or similar products
  • Participant currently owns a wearable and is willing to use and connect the wearable device
  • Willing to use personal smart phone, tablet, or personal computer with stable internet connection
  • Willing and able to comply with all study procedures
  • Willing to adhere to all study procedures, including lifestyle considerations and sign forms providing informed consent to participate in the study

You may not qualify if:

  • History or presence, on the basis of the health history, of clinically important condition or disease states
  • Is currently following, or planning to be on, a weight loss regimen
  • Weight loss or gain \>4.5 kg
  • History of gastrointestinal surgery for weight reducing purposes or gastrointestinal (GI) conditions
  • History of an eating disorder (e.g., anorexia nervosa or bulimia nervosa, binge eating) at the discretion of the Clinical Investigator.
  • History of unconventional sleep patterns (e.g., night shift) or diagnosed sleep disorder
  • Use of tobacco/nicotine products
  • Use of hemp/marijuana products
  • Unstable use of any prescription medication
  • Use of any medications(s) or dietary supplement(s), containing caffeine, or interacting with caffeine
  • Recent history of alcohol or substance abuse
  • Exposed to any non-registered drug product
  • Self-report of hypertension/high blood pressure without use of hypertensive medications
  • Any known allergy or intolerance to any ingredients contained in the study product
  • Any signs or symptoms of active infection of clinical relevance
  • +6 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Alethios, Inc.

San Francisco, California, 94109, United States

RECRUITING

Study Officials

  • Kristin Nieman, PhD

    Nlumn LLC

    PRINCIPAL INVESTIGATOR

Central Study Contacts

VP Product Innovation, Guayaki Sustainable Rainforest Products

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: This interventional trial focuses on evaluating the effects of the intervention on health and well-being.
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 12, 2026

First Posted

February 11, 2026

Study Start

January 5, 2026

Primary Completion

March 31, 2026

Study Completion

March 31, 2026

Last Updated

February 11, 2026

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share

Locations